Positions

Selected Publications

Academic Article

Year Title Altmetric
2017 Dynamics of the vaginal wall dose in HDR interstitial brachytherapy for gynecological cancer: Systematic analysis of phantom vs patient case.Medical Dosimetry.  43:237-242. 2017
2016 A novel phantom and procedure providing submillimeter accuracy in daily QA tests of accelerators used for stereotactic radiosurgery*.Journal of Applied Clinical Medical Physics.  17:246-253. 2016
2016 A novel phantom and procedure providing submillimeter accuracy in daily QA tests of accelerators used for stereotactic radiosurgery().Journal of Applied Clinical Medical Physics.  17:246-253. 2016
2014 End-to-end test of spatial accuracy in Gamma Knife treatments for trigeminal neuralgia.Medical Physics.  41:111703. 2014
2014 Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.Journal of Nuclear Medicine.  55:1636-1642. 2014
2014 Image-guided brachytherapy for cervical cancer: analysis of D2 cc hot spot in three-dimensional and anatomic factors affecting D2 cc hot spot in organs at risk.Brachytherapy.  13:203-209. 2014
2014 Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.Cancer Biotherapy and Radiopharmaceuticals.  29:12-17. 2014
2014 A technique using 99mTc-mebrofenin SPECT for radiotherapy treatment planning for liver cancers or metastases.Medical Dosimetry.  39:7-11. 2014
2013 Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.Cancer Biotherapy and Radiopharmaceuticals.  28:370-379. 2013
2013 Intraoperative ultrasound guidance during intracavitary brachytherapy applicator placement in cervical cancer: the University of Alabama at Birmingham experience.International Journal of Gynecological Cancer.  23:559-566. 2013
2012 Image-based 3D treatment planning for vaginal cylinder brachytherapy: dosimetric effects of bladder filling on organs at risk.International Journal of Radiation Oncology - Biology - Physics.  83:980-985. 2012
2012 SU-E-T-434: Use of Deformable Registration for Cumulated Dose Calculation in Image-Guided Intracavitary Bracytherapy for Cervical Cancer.Medical Physics.  39:3804. 2012
2011 Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.Cancer Biotherapy and Radiopharmaceuticals.  26:127-133. 2011
2010 The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: a case series.Endoscopy.  42:423-425. 2010
2010 Effects of bladder distension on organs at risk in 3D image-based planning of intracavitary brachytherapy for cervical cancer.International Journal of Radiation Oncology - Biology - Physics.  76:485-489. 2010
2010 Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.Journal of Nuclear Medicine.  51:150-157. 2010
2009 Performance of a commercial Macro Monte Carlo dose calculation algorithm for determining output factors of clinical electron fields.Technology in Cancer Research and Treatment.  8:307-314. 2009
2009 Development of an accelerated GVF semi-automatic contouring algorithm for radiotherapy treatment planning.Computers in Biology and Medicine.  39:650-656. 2009
2009 Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma.Journal of Clinical Oncology.  27:e13006. 2009
2009 MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.Journal of Nuclear Medicine.  50:644-652. 2009
2009 Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source.Journal of Applied Clinical Medical Physics.  10:2903. 2009
2009 Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR sourceJournal of Applied Clinical Medical Physics.  10:90-102. 2009
2008 Conventional high-dose-rate brachytherapy with concomitant complementary IMRT boost: a novel approach for improving cervical tumor dose coverage.International Journal of Radiation Oncology - Biology - Physics.  71:765-771. 2008
2008 A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.Journal of Nuclear Medicine.  49:279-284. 2008
2007 Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.Leukemia & Lymphoma.  48:1736-1744. 2007
2007 Image-based three-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: dose-volume histograms of the bladder, rectum, sigmoid colon, and small bowel.Brachytherapy.  6:187-194. 2007
2007 Intensity modulation with respiratory gating for radiotherapy of the pleural space.Medical Dosimetry.  32:16-22. 2007
2007 SU‐FF‐J‐78: 3‐D Target Localization at the End of Expiration Prior to Respiration‐Gated Radiotherapy TreatmentMedical Physics.  34:2386. 2007
2007 SU‐FF‐T‐372: Registration of Frameless High‐Field MRI to Low‐Field Frame‐Based MRI Images in Leksell Gamma‐Knife (LGK) RadiosurgeryMedical Physics.  34:2487. 2007
2007 TH‐C‐AUD‐03: Impact of Respiratory Motion On Helical Tomotherapy Dose Delivery: A Phantom Study with 3‐D Volumetric Dose MeasurementsMedical Physics.  34:2626-2627. 2007
2006 Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.International Journal of Radiation Oncology - Biology - Physics.  66:1192-1198. 2006
2006 Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.Clinical lymphoma.  7:236-238. 2006
2006 Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.Journal of Clinical Oncology.  24:3644-3650. 2006
2006 Comprehensive evaluation of a commercial macro Monte Carlo electron dose calculation implementation using a standard verification data set.Medical Physics.  33:1540-1551. 2006
2006 Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: a volumetric dose measurement study.Medical Physics.  33:1380-1387. 2006
2006 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.Journal of Nuclear Medicine.  47:534-542. 2006
2005 Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513))Cancer Biotherapy and Radiopharmaceuticals.  20:671. 2005
2005 Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.Cancer Biotherapy and Radiopharmaceuticals.  20:662-670. 2005
2005 Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.Cancer Biotherapy and Radiopharmaceuticals.  20:502-513. 2005
2005 Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.Cancer Biotherapy and Radiopharmaceuticals.  20:467-478. 2005
2005 High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.Clinical Cancer Research.  11:5920-5927. 2005
2005 Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.Cancer Biotherapy and Radiopharmaceuticals.  20:379-390. 2005
2005 Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.Journal of Nuclear Medicine.  46:1034-1041. 2005
2005 Clinically useful marrow dosimetry for targeted radionuclide therapy.Cancer Biotherapy and Radiopharmaceuticals.  20:119-122. 2005
2005 Imaging glioma extent with 131I-TM-601.Journal of Nuclear Medicine.  46:580-586. 2005
2005 Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.Journal of Nuclear Medicine.  46:642-651. 2005
2005 Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.Cancer Biotherapy and Radiopharmaceuticals.  20:110-118. 2005
2005 Determination of field size-dependent wedge factors from a few selected measurements.Journal of Applied Clinical Medical Physics.  6:51-60. 2005
2005 MO‐D‐I‐609‐07: Combined Scatter Subtraction and Digital Restoration of Ho‐166 Images for QuantificationMedical Physics.  32:2054. 2005
2005 Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice.Journal of Neuro-Oncology.  71:113-119. 2005
2005 SU‐EE‐A1‐04: Integrated Complementary IMRT Combined with Image‐Guided HDR Brachytherapy for Cancers of the Uterine CervixMedical Physics.  32:1902. 2005
2005 SU‐FF‐J‐123: Residual Tumor Motion in Respiratory Gated CT Treatment PlaningMedical Physics.  32:1948. 2005
2004 ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.Clinical Cancer Research.  10:7555-7565. 2004
2004 A dynamic supraclavicular field-matching technique for head-and-neck cancer patients treated with IMRT.International Journal of Radiation Oncology - Biology - Physics.  60:959-972. 2004
2004 Dose errors due to inhomogeneities in balloon catheter brachytherapy for breast cancer.International Journal of Radiation Oncology - Biology - Physics.  60:672-677. 2004
2004 Attenuation of intracavitary applicators in 192Ir-HDR brachytherapy.Medical Physics.  31:2097-2106. 2004
2004 Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.Blood.  104:227-236. 2004
2003 Validation of target volume and position in respiratory gated CT planning and treatment.Medical Physics.  30:3196-3205. 2003
2003 A novel monoclonal antibody design for radioimmunotherapy.Cancer Biotherapy and Radiopharmaceuticals.  18:751-759. 2003
2003 Custom step wedge blocking using dynamic multileaf collimation for parametrial pelvic boost irradiation following brachytherapy for carcinoma of the cervix.Medical Physics.  30:2699-2702. 2003
2003 Dosimetric effect of respiration-gated beam on IMRT delivery.Medical Physics.  30:2241-2252. 2003
2003 Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.Cancer Biotherapy and Radiopharmaceuticals.  18:393-404. 2003
2003 Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.Cancer Biotherapy and Radiopharmaceuticals.  18:209-215. 2003
2003 Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.Cancer Biotherapy and Radiopharmaceuticals.  18:231-237. 2003
2002 Assaying 192Ir line sources using a standard length well chamber.Medical Physics.  29:2692-2697. 2002
2002 Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation.International Journal of Radiation Oncology - Biology - Physics.  54:921-927. 2002
2002 A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.Clinical Cancer Research.  8:2806-2811. 2002
2002 Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.Journal of Nuclear Medicine.  43:1245-1253. 2002
2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy.Cancer.  94:1264-1269. 2002
2001 Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.Journal of Nuclear Medicine.  42:1324-1333. 2001
2001 Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.Clinical Cancer Research.  7:1561-1568. 2001
2000 A phase I study of90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphomaAnticancer Research.  20:3647-3655. 2000
2000 A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.Anticancer Research.  20:3647-3655. 2000
2000 Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.Clinical lymphoma.  1:118-126. 2000
2000 Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.Journal of Nuclear Medicine.  41:952-958. 2000
1999 A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.Journal of Nuclear Medicine.  40:2014-2020. 1999
1999 Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.Journal of Nuclear Medicine.  40:2102-2106. 1999
1999 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.Clinical Cancer Research.  5:3330s-3336s. 1999
1999 Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.Clinical Cancer Research.  5:3243s-3248s. 1999
1999 Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.Cancer Biotherapy and Radiopharmaceuticals.  14:363-369. 1999
1999 Strategies for developing effective radioimmunotherapy for solid tumors.Clinical Cancer Research.  5:3219s-3223s. 1999
1999 Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.Nuclear Medicine and Biology.  26:841-845. 1999
1999 Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.Journal of Nuclear Medicine.  40:1317-1326. 1999
1999 Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.Cancer Biotherapy and Radiopharmaceuticals.  14:167-176. 1999
1999 Dosimetry for radioimmunotherapy: a rapidly evolving field.Cancer Biotherapy and Radiopharmaceuticals.  14:67-70. 1999
1999 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.Clinical Cancer Research.  5:533-541. 1999
1999 67Cu- versus 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphomaClinical Cancer Research.  5:533-541. 1999
1999 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.Journal of Nuclear Medicine.  40:302-310. 1999
1999 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaJournal of Nuclear Medicine.  40:302-310. 1999
1998 Synergistic therapy of breast cancer with Y90-chimeric L6 and paclitaxel in the xenografted mouse model: Development of a clinical protocolAnticancer Research.  18:4011-4018. 1998
1998 Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.Clinical Cancer Research.  4:2483-2490. 1998
1998 Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.Journal of Clinical Oncology.  16:3246-3256. 1998
1998 Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.Cancer Biotherapy and Radiopharmaceuticals.  13:239-254. 1998
1998 A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.Journal of Nuclear Medicine.  39:1223-1229. 1998
1998 Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.Anticancer Research.  18:2779-2788. 1998
1998 Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot studyAnticancer Research.  18:2779-2788. 1998
1998 Quantification of iodine-131 in tumors using a threshold based on image contrast.European Journal of Nuclear Medicine.  25:497-502. 1998
1998 Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.Journal of Nuclear Medicine.  39:842-849. 1998
1998 Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.Cancer Biotherapy and Radiopharmaceuticals.  13:1-12. 1998
1997 Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.Cancer.  80:2576-2582. 1997
1997 Imaging for improved prediction of myelotoxicity after radioimmunotherapy.Cancer.  80:2558-2566. 1997
1997 Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.Cancer.  80:2553-2557. 1997
1997 Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.Journal of Nuclear Medicine.  38:1374-1378. 1997
1997 Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.Journal of Nuclear Medicine.  38:1180-1185. 1997
1997 Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.Clinical Cancer Research.  3:1253-1260. 1997
1997 Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancerAnticancer Research.  17:1735-1744. 1997
1997 Practical determination of organ S values for individual patients for therapy.Nuclear Medicine and Biology.  24:447-449. 1997
1997 Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.Anticancer Research.  17:1735-1744. 1997
1997 Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).Clinical Cancer Research.  3:71-79. 1997
1997 Practical determination of organ S values for individual patients for therapyNuclear Medicine and Biology.  24:447-449. 1997
1997 Reproducibility of operator processing for radiation dosimetry.Nuclear Medicine and Biology.  24:77-83. 1997
1996 Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.Journal of Nuclear Medicine.  37:1970-1975. 1996
1996 A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy.Nuclear Medicine and Biology.  23:525-532. 1996
1996 Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator.Journal of Nuclear Medicine.  37:302-306. 1996
1996 Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.Journal of Nuclear Medicine.  37:146-150. 1996
1995 Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignanciesCancer Research.  55. 1995
1995 Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.Cancer Research.  55:5893s-5898s. 1995
1995 Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expressionCancer Research.  55. 1995
1995 Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.Cancer Research.  55:5837s-5841s. 1995
1995 Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.Clinical Nuclear Medicine.  20:117-125. 1995
1994 Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter.Medical Physics.  21:1409-1417. 1994
1994 Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung.Journal of Nuclear Medicine.  35:1381-1389. 1994
1994 Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).Cancer.  73:1012-1022. 1994
1994 Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.Cancer.  73:1038-1048. 1994
1994 Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3)Cancer.  73:1012-1022. 1994
1994 Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a modelCancer.  73:1038-1048. 1994
1990 Photon correlation spectroscopy of the polarization signal from single muscle fibres.Journal of Muscle Research and Cell Motility.  11:137-146. 1990
1989 Polarization states of diffracted light. Changes accompanying fiber activation.Biophysical Journal.  56:595-605. 1989

Chapter

Year Title Altmetric
2010 Dosimetry for Targeted Radiotherapy.  473-506. 2010

Full Name

  • Sui Shen